瑞巴派特联合雷贝拉唑治疗慢性萎缩性胃炎的效果及对胃肠道激素和炎症因子的影响  

Efficacy of rebamipide combined with rabeprazole in treatment of chronic atrophic gastritis and its impact on gastrointestinal hormones and inflammatory factors

作　　者：陈静[1] 曲城圆 叶青龙 Chen Jing;Qu Cheng-yuan;Ye Qing-long(Department of Gastroenterology,Zhuhai Hospital of Guangdong Provincial People’s Hospital(Zhuhai Jinwan Central Hospital),Zhuhai 519000,China)

机构地区：[1]广东省人民医院珠海医院(珠海市金湾中心医院)消化内科,珠海519000

出　　处：《中国药物应用与监测》2024年第6期734-737,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的探讨瑞巴派特联合雷贝拉唑治疗慢性萎缩性胃炎的效果及对胃肠道激素、炎症因子的影响。方法选取2022年1月至2023年12月在广东省人民医院珠海医院就诊的168例慢性萎缩性胃炎患者进行研究。按照随机数字表法分为试验组对照组,两组完成观察各72例,对照组给予雷贝拉唑,试验组给予瑞巴派特+雷贝拉唑,持续治疗2个月,比较两组患者的临床疗效、胃肠道激素[降钙素基因相关肽(CGRP)、胃泌素(GAS)、表皮生长因子(EGF)]、炎症因子[白细胞介素(IL)-8、IL^(-1)1和肿瘤坏死因子α(TNF-α)]以及不良反应情况。结果试验组治疗有效率91.67%(66/72)高于对照组77.78%(56/72),差异有统计学意义(χ^(2)=5.365,P=0.021)。试验组治疗前CCPR、GAS、EGF分别为(27.17±4.28)ng·L^(-1)、(88.12±11.48)pg·mL^(-1)、(4.28±0.47)ng·L^(-1),与对照组的(26.78±4.37)ng·L^(-1)、(89.16±10.43)pg·mL^(-1)、(4.37±0.56)ng·L^(-1)比较,差异无统计学意义(t=0.541,P=0.589;t=0.569,P=0.570;t=1.045,P=0.298)。试验组治疗后CCPR、GAS、EGF分别为(40.39±5.71)ng·L^(-1)、(131.34±17.42)pg·mL^(-1)、(2.53±0.35)ng·L^(-1),与对照组的(35.24±4.93)ng·L^(-1)、(117.71±15.49)pg·mL^(-1)、(2.97±0.54)ng·L^(-1)比较,差异有统计学意义(t=5.793,P<0.001;t=4.961,P<0.001;t=5.802,P<0.001)。试验组治疗前IL-8、IL^(-1)1、TNF-α分别为(10.96±2.27)ng·L^(-1)、(71.28±7.23)ng·L^(-1)、(68.63±8.49)ng·L^(-1),与对照组的(10.53±2.21)ng·L^(-1)、(69.33±6.26)ng·L^(-1)、(67.58±9.55)ng·L^(-1)比较,差异无统计学意义(t=1.152,P=0.251;t=1.730,P=0.086;t=0.697,P=0.487)。试验组治疗后IL-8、IL^(-1)1、TNF-α分别为(7.08±1.26)ng·L^(-1)、(41.75±6.27)ng·L^(-1)、(52.87±5.63)ng·L^(-1),与对照组的(8.37±1.67)ng·L^(-1)、(47.52±6.35)ng·L^(-1)、(58.39±6.54)ng·L^(-1)比较,差异有统计学意义(t=5.232,P<0.001;t=5.486,P<0.001;t=5.428,P<0.001)。试验组总不良反应11.11%(8/72)与对照组8.33%(6/72)比较,差异无统计学Objective To investigate the efficacy of rebamipide combined with rabeprazole in treatment of chronic atrophic gastritis and its influences on gastrointestinal hormones and inflammatory factors.Methods A total of 168 patients with chronic atrophic gastritis treated in Zhuhai Hospital of Guangdong Provincial People’s Hospital between January 2022 and December 2023 were enrolled in this study.According to the random number table method,they were divided into the experimental group(n=72,treated with rebamipide in combination with rabeprazole)and control group(n=72,treated with rabeprazole alone).All patients in both groups were treated for 2 months.The clinical efficacy,gastrointestinal hormones(calcitonin gene-related peptide(CGRP),gastrin(GAS),epidermal growth factor(EGF)),inflammatory factors(interleukin(IL)-8,IL^(-1)1,tumor necrosis factor-α(TNF-α))and adverse reactions were compared between the two groups.Results The response rate of treatment was higher in the experimental group than in the control(91.67%(66/72)vs 77.78%(56/72),χ^(2)=5.365,P=0.021).Before treatment,there were no significant differences in CCPR,GAS and EGF between experimental group and the control((27.17±4.28)ng·L^(-1),(88.12±11.48)pg·mL^(-1),(4.28±0.47)ng·L^(-1)vs(26.78±4.37)ng·L^(-1),(89.16±10.43)pg·mL^(-1),(4.37±0.56)ng·L^(-1);t=0.541,P=0.589;t=0.569,P=0.570;t=1.045,P=0.298),but there were significant differences between the two groups after treatment((40.39±5.71)ng·L^(-1),(131.34±17.42)pg·mL^(-1),(2.53±0.35)ng·L^(-1)vs(35.24±4.93)ng·L^(-1),(117.71±15.49)pg·mL^(-1),(2.97±0.54)ng·L^(-1);t=5.793,P<0.001;t=4.961,P<0.001;t=5.802,P<0.001).Before treatment,there were no significant differences in IL-8,IL^(-1)1 or TNF-αbetween the experimental group and the control((10.96±2.27)ng·L^(-1),(71.28±7.23)ng·L^(-1),(68.63±8.49)ng·L^(-1)vs(10.53±2.21)ng·L^(-1),(69.33±6.26)ng·L^(-1),(67.58±9.55)ng·L^(-1);t=1.152,P=0.251;t=1.730,P=0.086;t=0.697,P=0.487),but there were significant differences between the two groups a

关 键 词：瑞巴派特 雷贝拉唑 慢性萎缩性胃炎 胃肠道激素 炎症因子 

分 类 号：R573.32[医药卫生—消化系统]